HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.

AbstractOBJECTIVE:
To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had a sustained effect on radiological damage for a total of 4 years.
METHODS:
A total of 150 of 211 eligible patients with RA who had been randomised to the 7.5 mg prednisolone group (P) or no prednisolone group (NoP) in addition to the initial disease-modifying antirheumatic drugs were included. Radiographs of hands and feet were scored using the Sharp-van der Heijde scoring method. A patient was considered to be in remission if the 28-joint count disease activity score was <2.6.
RESULTS:
Mean (SD) age was 53 (14) and 57 (12) years for the patients in the P and NoP groups, respectively. 64% were female, 64% rheumatoid factor positive, and disease duration at baseline was 6 months. At 2 years the proportion of patients in remission in the P and NoP groups was 55 vs 30%, p = 0.003. Longitudinal analysis showed that over the entire course of the disease, patients on prednisolone had a higher probability of being in remission. Patients in remission at 2 years, compared with those not in remission, had significantly lower total Sharp score, erosion score and joint space narrowing score at 2 and 4 years. The changes in bone mineral density during the 4 years did not differ between those in remission and those with active disease, and were similar in the two treatment groups.
CONCLUSIONS:
Prednisolone 7.5 mg daily in addition to disease-modifying anti-rheumatic drugs increases the rate of remission in patients with early RA, which has a beneficial and sustained effect on radiological damage.
AuthorsI Hafström, K Albertsson, A Boonen, D van der Heijde, R Landewé, B Svensson, BARFOT Study Group
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 68 Issue 4 Pg. 508-13 (Apr 2009) ISSN: 1468-2060 [Electronic] England
PMID18420939 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antirheumatic Agents
  • Glucocorticoids
  • Prednisolone
Topics
  • Adult
  • Aged
  • Antirheumatic Agents (administration & dosage, therapeutic use)
  • Arthritis, Rheumatoid (diagnostic imaging, drug therapy)
  • Bone Density (drug effects)
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Glucocorticoids (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Prednisolone (administration & dosage, therapeutic use)
  • Radiography
  • Remission Induction (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: